This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bruch-Gerharz, D. Articles by Kolb-Bachofen, V. Search for Related Content PubMed PubMed Citation Articles by Bruch-Gerharz, D. Articles by Kolb-Bachofen, V.

(American Journal of Pathology. 2003;162:203-211.)
© 2003 American Society for Investigative Pathology

Regular Articles

Arginase 1 Overexpression in Psoriasis

Limitation of Inducible Nitric Oxide Synthase Activity as a Molecular Mechanism for Keratinocyte Hyperproliferation

Daniela Bruch-Gerharz^*, Oliver Schnorr^*, Christoph Suschek^*, Karl-Friedrich Beck, Josef Pfeilschifter, Thomas Ruzicka and Victoria Kolb-Bachofen^*

From the Research Group Immunobiology,^*Biomedical Research Center, and the Department of Dermatology,University of Duesseldorf, Duesseldorf; and the Institute of Pharmacology,University of Frankfurt, Frankfurt, Germany

Abnormal proliferation of keratinocytes in the skin appears crucial to the pathogenesis of psoriasis, but the underlying mechanisms remain unknown. Nitric oxide (NO), released from keratinocytes at high concentrations, is considered a key inhibitor of cellular proliferation and inducer of differentiation in vitro. Although high-output NO synthesis is suggested by the expression of inducible NO synthase (iNOS) mRNA and protein in psoriasis lesions, the pronounced hyperproliferation of psoriatic keratinocytes may indicate that iNOS activity is too low to effectively deliver anti-proliferative NO concentrations. Here we show that arginase 1 (ARG1), which substantially participates in the regulation of iNOS activity by competing for the common substrate L-arginine, is highly overexpressed in the hyperproliferative psoriatic epidermis and is co-expressed with iNOS. Expression of L-arginine transporter molecules is found to be normal. Treatment of primary cultured keratinocytes with Th1-cytokines, as present in a psoriatic environment, leads to de novo expression of iNOS but concomitantly a significant down-regulation of ARG1. Persistent ARG1 overexpression in psoriasis lesions, therefore, may represent a disease-associated deviation from normal expression patterns. Furthermore, the culturing of activated keratinocytes in the presence of an ARG inhibitor results in a twofold increase in nitrite accumulation providing evidence for an L-arginine substrate competition in human keratinocytes. High-output NO synthesis is indeed associated with a significant decrease in cellular proliferation as shown by down-regulation of Ki67 expression in cultured keratinocytes but also in short-term organ cultures of normal human skin. In summary, our data demonstrate for the first time a link between a human inflammatory skin disease, limited iNOS activity, and ARG1 overexpression. This link may have substantial implications for the pathophysiology of psoriasis and the development of new treatment strategies.

This article has been cited by other articles:

				K. Jager, U. Bonisch, M. Risch, D. Worlitzsch, and F. Paulsen Detection and Regulation of Cationic Amino Acid Transporters in Healthy and Diseased Ocular Surface Invest. Ophthalmol. Vis. Sci., March 1, 2009; 50(3): 1112 - 1121. [Abstract] [Full Text] [PDF]

				B.-S. Choi, I. C. Martinez-Falero, C. Corset, M. Munder, M. Modolell, I. Muller, and P. Kropf Differential impact of L-arginine deprivation on the activation and effector functions of T cells and macrophages J. Leukoc. Biol., February 1, 2009; 85(2): 268 - 277. [Abstract] [Full Text] [PDF]

				K. Ckless, A. van der Vliet, and Y. Janssen-Heininger Arginase Modulates NF-{kappa}B Activity via a Nitric Oxide-Dependent Mechanism Am. J. Respir. Cell Mol. Biol., June 1, 2007; 36(6): 645 - 653. [Abstract] [Full Text] [PDF]

				S. M. Morris Jr. Arginine Metabolism: Boundaries of Our Knowledge J. Nutr., June 1, 2007; 137(6): 1602S - 1609S. [Abstract] [Full Text] [PDF]

				V. Kolb-Bachofen, A. Kuhn, and C. V. Suschek The role of nitric oxide Rheumatology, October 1, 2006; 45(suppl_3): iii17 - iii19. [Abstract] [Full Text] [PDF]

				N. Thengchaisri, T. W. Hein, W. Wang, X. Xu, Z. Li, T. W. Fossum, and L. Kuo Upregulation of Arginase by H2O2 Impairs Endothelium-Dependent Nitric Oxide-Mediated Dilation of Coronary Arterioles Arterioscler. Thromb. Vasc. Biol., September 1, 2006; 26(9): 2035 - 2042. [Abstract] [Full Text] [PDF]

				M. Munder, F. Mollinedo, J. Calafat, J. Canchado, C. Gil-Lamaignere, J. M. Fuentes, C. Luckner, G. Doschko, G. Soler, K. Eichmann, et al. Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity Blood, March 15, 2005; 105(6): 2549 - 2556. [Abstract] [Full Text] [PDF]

				M. Mori and T. Gotoh Arginine Metabolic Enzymes, Nitric Oxide and Infection J. Nutr., October 1, 2004; 134(10): 2820S - 2825S. [Abstract] [Full Text] [PDF]

				M. R. Namazi and V. Kolb-Bachofen Explaining Decreased Nitric Oxide Production in Psoriatic Lesions: Arginase 1 Overexpression versus Calcitonin Gene-Related Peptide Am. J. Pathol., December 1, 2003; 163(6): 2642 - 2643. [Full Text]